Edgar Filing: MARRONE BIO INNOVATIONS INC - Form 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION OMB

MARRONE BIO INNOVATIONS INC

Form 4

December 15, 2015 **FORM 4**

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549									3235-0287
Check this box								Number: Expires:	January 31,
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Estimated average burden hours per response O. O. O. O. O. O. O. O. O.									
(Print or Type F	Responses)								
1. Name and A Marrone Par	Symbol	Name and ONE BIO BII]				5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
(Last) C/O MARR INNOVATI AVENUE	Earliest Transaction Pay/Year) 015				X Director 10% Owner X Officer (give title Other (specify below) below) CEO and President				
DAVIS, CA	ndment, Date Original th/Day/Year)				6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City)	(State) (Zi	ip) Table	e I - Non-De	erivative S	ecurit	ies Acq	uired, Disposed of	or Beneficial	v Owned
1.Title of Security (Instr. 3)	2. Transaction Date 2 (Month/Day/Year) E	3. 4. Securities Acquired Transaction(A) or Disposed of (D) Code (Instr. 3, 4 and 5) (Instr. 8) (A) or Code V Amount (D) Price				5. Amount of Securities Beneficially Owned	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of	
Common Stock	12/11/2015		M	20,000	A	\$ 0.47	751,931	D	
Common Stock							53,134	I	Jointly with Spouse
Common Stock							6,442	I	See Footnote (1)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

OMB APPROVAL

Edgar Filing: MARRONE BIO INNOVATIONS INC - Form 4

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

Γ

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. Number of actiorDerivative Securities 8) Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	\$ 0.47	12/11/2015		M	2	20,000	<u>(2)</u>	05/01/2017	Common Stock	20,000

Reporting Owners

Reporting Owner Name / Address Relationships

Director 10% Owner Officer Other

CEO and President

Marrone Pamela G

C/O MARRONE BIO INNOVATIONS, INC.

1540 DREW AVENUE DAVIS, CA 95618

Signatures

/s/ Pamela G.
Marrone 12/15/2015

**Signature of Date
Reporting Person

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

X

- (1) Ownership is held by Florence H. Marrone TOD Pamela G. Marrone.
- (2) The options vested with respect to 25% of the total 53,378 shares subject to the option on the grant date of May 1, 2007, with 2.083% of the total shares subject to the option vesting monthly thereafter.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2